Trial Profile
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; HIV-1 infections
- Focus Therapeutic Use
- 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
- 23 Jan 2013 Actual patient number changed from 70 to 73 according to ClinicalTrials.gov.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.